The document discusses a new hypothesis for Alzheimer's disease (AD) treatment, focusing on homocysteic acid (HA) as a pathogen. It reports on a clinical trial using HBF brain food, which purportedly recovers cognitive impairment in AD patients by reducing HA levels in the blood. The trial involved 61 patients, showing improvement in cognitive scores after consuming the brain food.
documents/EFTA01196423.pdf
{}